NASDAQ · PROF

Profound Medical Corp.

$7.33 +$0.07 (+0.96%) 1D Market open

Key Metrics

$263.81M
Market cap
P/E · TTM
$18.81M
Revenue · TTM
−$38.90M
Net income
EPS · TTM $-1.29
Dividend yield
Free cash flow
Beta · 1Y 1.74
EBITDA · TTM −$38.31M
Gross margin 71.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 25
    The stock moved +13.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 25
  • Mar 20
    From its Feb 26 high, the share price fell 35%.

    Peak close $7.78 on Feb 26; trough close $5.06 on Mar 20. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • Mar 6
    The stock moved -29.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$263.81M
Enterprise value$222.52M
Shares outstanding36.3M
52-wk range$3.76 – $8.95
Avg volume · 20D69.8K
Net cash $41.29M
Book value / share$1.98
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Profound Medical Corp.
IPO dateMay 9, 2016
Employees162

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S14.02
P/FCF
EV/EBITDA
EV/Sales11.83
Graham №

Profitability

Gross 71.1%
Operating -205.5%
Net -206.8%
FCF
ROE / ROIC -64.9% · -214.5%

Financial Health

Current ratio6.56
Quick ratio5.71
Debt / equity0.15
Debt / EBITDA -0.23
Net cash $41.29M
Working capital$58.92M

Cash Flow · TTM

Operating CF −$38.51M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

5.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings